Member access

4-Traders Homepage  >  Shares  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

0
Real-time Quote. Real-time TRADEGATE AG - 01/30 10:02:18 pm
68.6350 EUR   -1.01%
01/12 UCB : Update of transparency notification UCB SA/NV
01/09 DERMIRA : and UCB announce start of Phase 3 program for CIMZIA (cert..
01/07 UCB : Acquisition of own shares
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Deutsche Boerse Ag
01/26/2015 01/27/2015 01/28/2015 01/29/2015 01/30/2015 Date
69.54(c) 70.197(c) 70.154(c) 69.86(c) 69.338(c) Last
0 0 0 75 0 Volume
+1.78% +0.94% -0.06% -0.42% -0.75% Change
More quotes
Company
UCB SA is a biopharmaceutical company that engages in the research, development and commercialization of innovative drugs in the fields of central nervous system and immunology disorders.It focuses on the discovery and development of innovative medicines and solutions to transform the lives of... 
Sector
Pharmaceuticals
Calendar
02/25Earnings Release
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 3 398 M
EBIT 2014 452 M
Net income 2014 241 M
Debt 2014 1 335 M
Yield 2014 1,55%
Sales 2015 3 660 M
EBIT 2015 582 M
Net income 2015 343 M
Debt 2015 1 168 M
Yield 2015 1,73%
PER 2014 54,73
PER 2015 37,12
EV / Sales 2014 4,34x
EV / Sales 2015 3,98x
Capitalization 13 415 M
More Financials
Latest news on UCB SA
01/28 UCB : announces US and EU regulatory filings for the investigational antiepilept..
01/12 UCB : Update of transparency notification UCB SA/NV
01/09 DERMIRA : and UCB announce start of Phase 3 program for CIMZIA (certolizumab peg..
01/07 UCB : Acquisition of own shares
2014 UCB : Selects Cegedim Relationship Management Mobile Intelligence Cloud Platform
2014 UCB : "Method for Producing Protein" in Patent Application Approval Process
2014DJUCB : Advent, Avista End Acquisition Agreement
2014 UCB : Taps Cegedim Relationship Management Mobile Intelligence Cloud Platform
More news
Sector news Biopharmaceuticals
09:15a JOHNSON & JOHNSON : Former FDA chief calls J&J misleading on Risperdal
01/30 SANOFI : 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana..
01/30 ABBVIE : breakup with Shire torpedoes 4th quarter, 2014 results
Plus d'actualités du secteur Biopharmaceuticals
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF